GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Astrazeneca Plc (AZN) [hlAlert]

Rating:
Underperform
AZN
up 5.82 %

Astrazeneca Plc (AZN) downgraded to Underperform by BofA/Merrill

Posted on: Monday,  Mar 3, 2014  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Underperform Astrazeneca Plc (NYSE: AZN) on 03/03/2014, when the stock price was $33.45. Since
then, Astrazeneca Plc has lost 5.50% as of 01/19/2016's recent price of $31.61.
If you would have followed this BofA/Merrill's recommendation on AZN, you would have gained 5.82% of your investment in 687 days.

AstraZeneca PLC (AstraZeneca) is engaged in the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products for important areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. The Company?s product portfolio comprise: Arimidex, Crestor, Nexium, Seroquel and Symbicort. It has operations in various markets, such as China, United Kingdom, Sweden and the United States. It has 26 manufacturing sites in 18 countries. Cardiovascular product pipeline includes Saxagliptin, Dapagliflozin, Atherosclerosis/dyslipidaemia, Thrombosis and Atrial fibrillation. Gastrointestinal pipeline includes life cycle management initiatives. AstraZeneca?s Infection pipeline MedImmune and Dedicated tuberculosis (TB) research. Oncology product pipeline includes Zactima (vandetanib), Zactima (vandetanib), ZD4054 and MedImmune.

BofA/Merrill
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/3/2014 8:25 AM Sell
None
33.45
as of 10/17/2014
1 Week up  0.87 %
1 Month up  7.43 %
3 Months up  7.03 %
1 YTD down  -1.36 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/28/2013 8:25 AM Hold
None
26.52
9/10/2012 8:25 AM Sell
None
23.24

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy